Annual Meeting 2026 Press Program | Newsroom

For decades, certain genetic mutations in cancer were labeled “undruggable.” They were the fortress walls that traditional chemotherapy couldn’t breach. But we are currently witnessing a seismic shift in oncology. The focus has moved from broad-spectrum attacks to surgical precision, targeting the very molecular switches that drive tumor growth.

The emergence of next-generation inhibitors and “biological missiles” is not just an incremental improvement; it is a fundamental redesign of how we treat advanced malignancies, particularly in lung and ovarian cancers.

The End of the “Undruggable” Era: The KRAS Revolution

For years, the KRAS protein was the “holy grail” of cancer research. It acts like an on-off switch for cell growth; when mutated, the switch gets stuck in the “on” position, leading to uncontrolled tumor proliferation. This is especially prevalent in non-small cell lung cancer (NSCLC) and pancreatic cancer.

The breakthrough lies in specificity. We are no longer looking for a single key to unlock every KRAS mutation. Instead, researchers are developing inhibitors tailored to specific mutations, such as G12C and G12D.

Next-generation inhibitors like Elisrasib and Zoldonrasib represent this new wave. By targeting the “on” state of the protein (KRAS-ON inhibitors), these therapies can potentially offer more durable responses and overcome the resistance that often plagues earlier generations of targeted drugs.

The future trend here is Pan-KRAS inhibition. While G12C and G12D targeting is a massive leap, the ultimate goal is a therapy that can shut down multiple KRAS mutations simultaneously, preventing the cancer from “switching” mutations to survive.

Biological Missiles: The Rise of Antibody-Drug Conjugates (ADCs)

If KRAS inhibitors are the surgeons, Antibody-Drug Conjugates (ADCs) are the guided missiles of oncology. An ADC consists of three parts: a monoclonal antibody (the GPS), a chemical linker, and a potent cytotoxic payload (the warhead).

This technology is proving revolutionary for platinum-resistant ovarian cancer. In many cases, ovarian cancer initially responds to platinum-based chemotherapy but eventually develops resistance, leaving patients with limited options. ADCs bypass this resistance by delivering the chemotherapy directly inside the cancer cell, sparing healthy tissue and reducing systemic toxicity.

Recent data suggests that by targeting specific surface proteins on ovarian cancer cells, ADCs can induce significant tumor shrinkage even in patients who have failed multiple lines of standard therapy. This shift toward precision delivery systems is reducing the “shotgun approach” of traditional chemo.

The Next Frontier: Combination Strategies and Adaptive Therapy

The biggest challenge in oncology isn’t just starting a treatment—it’s stopping the cancer from adapting. Tumors are biologically cunning; they locate “bypass tracks” to keep growing even when one pathway is blocked.

The future of cancer care is moving toward Combination Therapy. Imagine a regimen where a KRAS inhibitor shuts down the primary growth signal, while an ADC destroys the remaining bulk of the tumor, and an immunotherapy agent primes the immune system to hunt down any leftover cells.

We are also seeing a trend toward Adaptive Therapy, where treatment is adjusted in real-time based on liquid biopsies (blood tests that detect circulating tumor DNA). Instead of waiting for a scan to present a tumor has grown, doctors can detect resistance mutations in the blood and switch the drug before the patient even feels a symptom.

Key Trends at a Glance

• From Broad to Bespoke: Shifting from “lung cancer drugs” to “G12D-specific inhibitors.”
• Toxicity Reduction: Using ADCs to deliver high-potency drugs only to malignant cells.
• Resistance Management: Using combination cocktails to block multiple escape routes for the cancer.

Frequently Asked Questions